Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanepitant SCHEMBL14421491 | 1.00 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL30695554 | 1.00 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL30522773 | 1.00 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL121512 | 1.00 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL7823239 | 0.99 | TACR1 (0.99) | TACR1 | |
| Lanepitant SCHEMBL9079078 | 0.99 | TACR1 (0.99) | TACR1 | |
| Lanepitant SCHEMBL7833331 | 0.99 | TACR1 (0.97) | TACR1 | |
| Lanepitant SCHEMBL8748971 | 0.98 | TACR1 (0.96) | TACR1 | |
| SCHEMBL29407152 | 0.94 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6760488 | 0.94 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | claimed |
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12390454-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3645120-B1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORP (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | disclosed |
| US-12023315-B2 | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | SOMERSET THERAPEUTICS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11813247-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813248-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11752141-B2 | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | DAS-MG, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-1999009987-A1 | METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999007374-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007376-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007373-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007375-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998047514-A1 | USE OF AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR TREATING OBESITY | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| WO-1997002824-A1 | USE OF A TACHYKININ ANTAGONIST AND A MUSCARINIC ANTAGONIST AND/OR AN ANTIHISTAMINE TO TREAT MOTION SICKNESS | MERCK SHARP & DOHME LIMITED (GB) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | TACR1 34/4885 |
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | TACR1 1/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | TACR1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.